

## DIAGNOSING ALZHEIMER'S DISEASE THROUGH DETECTION OF TAU PROTEIN IN HUMAN BLOOD USING ULTRASENSITIVE NANO-GAP SENSOR: FROM CSF TO BLOOD

- Nanosensors related to human cognition and brain research

Presenting author: Ph D. Soo Hyun Lee

Center for BioMicrosystems Brain Science Institute Korea Institute of Science and Technology

Venue: Qualcomm Institute, UCSD

Korea Institute of Science and Technology

# CONTENTS

#### Introduction

- Alzheimer's Diseases and Diagnosis Methods
- Alzheimer's Biomarkers: Aß, Tau, NfL, Neurogranin
- Why we choose Tau and Tau PTM as a novel biomarker?

#### Magnetic Beads Based Nanogap Sensor


- Sensing Platform for Detecting Tau, Tau PTM
- Sensing Mechanism of Bead Based Nanogap Sensor
- Experimental Results
  - Impedance Analysis using Tau recombinant
  - Limit of Detection and Dynamic Range
  - The Results of **AD Mouse Blood** (plasma)
  - The Results of Human Blood (plasma)
- Summary
- Acknowledgements



# **ALZHEIMER'S DISEASES**



#### What is Alzheimer's disease?



# **DIAGNOSIS METHODS**



## **Current diagnostic methods**

**MMSE** scoring


**Brain Imaging (PET)** 

# Biomarker quantification in CSF and blood




NC 29 (±1.4) MCI 27 (±1.6) AD 19 (±4.9)

Zetterberg, H.; Plasma tau levels in Alzheimer's disease. Alzheimer's research & therapy 2013, 5 (2), 9.



https://medcitynews.com/2016/05/brain-imaging-agent-alzheimer/



Yang, T et al. Alzheimer's research & therapy 2015, 7(1), 14.


# **ALZHEIMER'S BIOMARKERS**



A A A A A A A A A A A A A A A A A A A	Sensing platform	Journal/year	Title (corresponding)	Protein form	Limit of detection	Dynamic range	Sensitivity	Specificity
Amyloid beta https://commons.wikimedia.org/wiki/File:Amyloid-beta- 42_1IYT.png	IP-MS	Nature 554, 249-254	High performance plasma amyloid-β biomarkers for Alzheimer's disease (Katsuhiko Yanagisawa)	APP 669- 711/Abeta 1- 42	2.5Da	~180ng/ml	96.7% (AUC)	81.0% (AUC)
		2018						
https://en.wikipedia.org/wiki/Tau_protem#/media/Fil e:PDB_1i8h_EBI.jpg	IMR	Journal of Alzheimer's Disease, vol. 61, no. 4, pp. 1323-1332	Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer's disease (Shieh-Yueh Yang)	Tau	0.0028 pg/ml	0.001- 10000pg/ml	0.793 (ROC)	0.836 (ROC)
		2018						
NfL	Digital ELISA	Alzheimer's Research & Therapy 10:71	Plasma neurofilament light as a potential biomarker of neurodegeneration in	nfl	0.62 pg/ml	unknown	0.84 (ROC)	0.78 (ROC)
https://www.labmedica.com/molecular-		2018	Alzheimer's disease (Piotr Lewczuk)					
diagnostics/articles/294777864/neurofilament-light- considered-as-niv-biomarker-for-alzheimers-disease.html								
Neurogranin https://www.ebi.ac.uk/pdbe/entry/pdb/4e50/analysis	ELISA	Alzheimer's & Dimentia 11 1461- 1469	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease (Eugeen Vanmechelen)	neurogranin	3 pg/ml	3-2000 pg/ml	x	x
		2015						

# CURRENT DETECTION METHODS USING BIOMARKERS IN BLOOD






# WHY WE CHOOSE TAU AND TAU PTM AS A NOVEL BIOMARKER

- Prognosis monitoring
- P tau and O-g Tau
- Ratio: P tau/tau vs. O-g tau/tau

## WHY WE CHOOSE TAU AND TAU PTM AS A NOVEL BIOMARKER: PROGNOSIS MONITORING






 Brain Imaging (PET) can be diagnosed after the progression of Alzheimer's diseases


AD : Alzheimer's diseases


- Aβ is unable to prognosis because it is being saturated quickly
- Tau is more suitable for monitoring Alzheimer's disease by detecting concentration of Tau or P Tau continuously

이 그래프의 reference 추가하기

# MAGNETIC BEADS BASED NANOGAP SENSOR









# NANOGAP SENSOR PLATFORM FOR DETECTING TAU, O-G TAU, AND P TAU






Contact type: WE, CE, RE

#### SEM image of well




Empty hole




20x20 array

**Sensing part** 

Bead occupied





## SENSING MECHANISM OF **MAGNETIC BEAD BASED NANOGAP SENSOR**

**Developed sensor** 



#### **Conventional EC sensor**




**Faradaic type** 

Nyquist plot lmaginary **R**<sub>CT</sub> increase Before conjugation After conjugation Real


Before conjugation

The interaction of the charged redox species with the charged probe layer can significantly impact R<sub>ct</sub>




After conjugation Impedance increase Real

It is common to rationalize changes in Csurf as occurring due to displacement of water and ions from the surface upon target binding.




## SENSING MECHANISM OF MAGNETIC BEAD BASED NANOGAP SENSOR







## AD diagnostic and prognosis monitoring using tau PTM analysis



U.S. patent, "Method for monitoring post-translational modification of protein", 15/696302, notice of allowance EU patent, "Method for monitoring post-translational modification of protein", 17895180.2, patent pending


# **EXPERIMENTAL RESULTS**

- Impedance analysis using Tau recombinant
- Limit of Detection and Dynamic Range using cell lysates
- The results of AD mouse blood
- The results of Human blood

# The 16th U.S.-KoreaEXPERIMENTAL RESULTS:Forum onLIMIT OF DETECTION AND DYNAMIC RANGENanotechnologyUSING TAU RECOMBINANT



#### Tau Recombinant measurement (Dynamic Range)



- Tau-441 human, recombinant, 2N4R
- Concentration of Tau protein range: 50 fg/ml ~ 500 pg/ml

#### **EXPERIMENTAL RESULTS:** The 16th U.S.-Korea LIMIT OF DETECTION AND DYNAMIC RANGE Nanotechnology **USING CELL LYSATES**

LOD

DR

10 pg/ml

10 pg/ml~ ug/ml




0.5 fg/ml

~500 pg/ml

0.5 fg/ml





- Ultra-high sensitivity
- Wide Dynamic range


LOD : Limit of Detection **DR** : Dynamic Range

Forum on

Lim, S., et al. (2015). "Monitoring of intracellular tau aggregation regulated by OGA/OGT inhibitors ." International journal of molecular sciences 16(9): 20212-20224.


0~360 pg/ml

19 fg/ml



# EXPERIMENTAL RESULTS:









✓ Nanogap sensor platform was successfully developed to measure Tau and Tau PTM in blood for AD's diagnosis and prognosis

 ✓ Tau, O-g tau, and P tau were measured and analyzed using cell lysates (Tau-BiFC), Tau 301pL mouse blood, and human blood.

✓ As a novel biomarker to diagnose AD using blood, *Taumeter* (P tau/O-g tau) is suggested and measured.

✓ Taumeter from mouse and human bloods can improve diagnostic accuracy

✓ Taumeter can be a promising biomarker to diagnose and prognose AD



